Lucid Capital analyst Dev Prasad raised the firm’s price target on InflaRx (IFRX) to $24 from $3 and keeps a Buy rating on the shares, stating that INF904 demonstrated a “differentiated, potentially best-in-class” profile in the phase 2a dataset for hidradentis suppurativa.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- Buy Rating for InflaRx: Promising Phase 2a Results of INF904 Drive Optimism
- InflaRx price target raised to $22 from $10 at Guggenheim
- InflaRx reports Phase 2a data for INF904 in HS, CSU
- InflaRx Announces Positive Phase 2a Results for INF904 in HS and CSU
- InflaRx Reports Q3 2025 Financial Results Highlighting Operational Challenges